Table 4. Progression to Late Age-Related Macular Degeneration from Early Age-Related Macular Degeneration among AGES participants who Completed both Retinal Examinations (N=2868)

Baseline Characteristic	No. at Risk*	Late AMD % (N)
Overall	563	22.7% (128)
Age		
≤ 69 years	47	12.8% (6)
70-74 years	144	11.8% (17)
75-79 years	190	24.7% (47)
80-84 years	159	32.7% (52)
85+ years	23	26.1% (6)
Sex		
Men	239	18.0% (43)
Women	324	26.2% (85)
Smoking Status		
Never Smokers	234	23.9% (56)
Former Smokers	265	21.5% (57)
Current Smokers	63	23.8% (15)
Cod Liver Oil Use		
Absent	233	25.3% (59)
Present	330	20.9% (69)
Hypertension		
Absent	112	23.2% (26)
Present	451	22.6% (102)
Pulse Pressure, as quartiles		
Q1 (< 55 mmHg)	139	21.6% (30)
Q2 (55-64 mmHg)	139	23.7% (33)
Q3 (65-76 mmHg)	130	23.1% (30)
Q4 (> 76 mmHg)	155	22.6% (35)
Diabetes		
Absent	500	22.8% (114)
Present	63	22.2% (14)
BMI, as quartiles		
Q1 (< 24.39 kg/m^2)	152	21.7% (33)
Q2 (24.39-26.95 kg/m^2)	132	20.5% (27)
Q3 (26.96-29.68 kg/m^2)	146	25.3% (37)
Q4 (> 29.68 kg/m^2)	133	23.3% (31)
Total Cholesterol, as quartiles		
Q1 (< 4.9 mmol/L)	152	24.3% (37)
Q2 (4.9-5.5 mmol/L)	121	20.7% (25)
Q3 (5.6-6.3 mmol/L)	145	23.5% (34)
Q4 (> 6.3 mmol/L)	145	22.1% (32)
HDL Cholesterol, as quartiles		
Q1 (< 1.27 mmol/L)	118	22.9% (27)
Q2 (1.28-1.52 mmol/L)	153	19.6% (30)
Q3 (1.53-1.83 mmol/L)	136	25.0% (34)
Q4 (> 1.83 mmol/L)	156	23.7% (37)
C-Reactive Protein		
Low (< 1 mg/L)	133	18.8% (25)
Moderate (1-3 mg/L)	262	23.7% (62)
High (> 3 mg/L)	168	24.4% (41)

AGES=Age, Gene/Environment Susceptibility-Reykjavik Study; AMD=age-related macular degeneration; BMI=body mass index;

HDL=high-density lipoprotein

Progression defined as exhibiting early AMD at baseline examination but exhibiting late AMD at the follow-up examination.

* Participants exhibited early AMD at baseline examination.